Potentially interesting setup developing in $PEPG ahead of conference week.
Tiny market cap
FDA Fast Track + Orphan Drug designation
Late-breaking oral presentation Thursday by CEO
Presentation wording specifically mentions “strong splicing correction” and “acceptable safety profile”
Stock got destroyed after FDA hold concerns earlier this year but has been basing around long term support in the 1.40s and keeps reclaiming 1.50.
Interesting part is nobody seems to be talking about it yet. Stocktwits dead quiet, Reddit barely mentioning it, volume still relatively low compared to prior runs.
If sentiment flips and volume comes in after conference slides/presentation this could move violently considering how compressed the chart is from previous levels.
Not saying guaranteed squeeze obviously, but definitely one of the more interesting under-the-radar biotech setups this week imo. Watching 1.60 closely for confirmation.